Ketanserin: A novel cardiovascular drug
- 1 May 1986
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 8 (1-4), 159-172
- https://doi.org/10.1002/ddr.430080119
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Chronic effect of ketanserin in mild to moderate essential hypertension.Hypertension, 1986
- Effects of Ketanserin, a 5-HT2-Receptor Antagonist, on the Blood Flow Response to Temperature Changes in the Diabetic FootThe Journal of Clinical Pharmacology, 1985
- Selective 5‐HT2 receptor blockade in exercise‐induced asthmaClinical and Experimental Allergy, 1985
- The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseasesInflammation Research, 1985
- The Effect of Ketanserin on Blood Pressure and Biochemical Parameters in Treated Patients with Essential HypertensionClinical and Experimental Hypertension. Part A: Theory and Practice, 1984
- 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.Hypertension, 1984
- Ketanserin in HypertensionActa Medica Scandinavica, 1983
- Ketanserin in essential hypertension: Effects during rest and exerciseEuropean Journal of Clinical Pharmacology, 1983
- Inhibition of 5-hydroxytryptamine-induced and-amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonistInflammation Research, 1982
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981